Axitinib: A Key Tyrosine Kinase Inhibitor for Cancer Therapy
Discover the power of Axitinib (319460-85-0) in targeting cancer angiogenesis and advancing treatment options.
Get a Quote & SampleProduct Core Value
Axitinib
Axitinib is a highly potent and selective oral tyrosine kinase inhibitor that targets the vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3), as well as platelet-derived growth factor receptor (PDGFR). This targeted inhibition disrupts tumor angiogenesis, a critical process for tumor growth and metastasis. It has been approved by regulatory bodies for the treatment of advanced renal cell carcinoma (RCC) and is extensively researched for its efficacy in various other cancer types.
- Axitinib CAS 319460-85-0 is a crucial compound in modern oncology, offering a targeted approach to cancer treatment.
- As a potent tyrosine kinase inhibitor for RCC, it provides a vital therapeutic option for patients battling advanced stages of the disease.
- Its mechanism as an anti-angiogenic therapy for cancer makes it a subject of interest for treating a wide spectrum of malignancies.
- The dual action as a VEGF and PDGF inhibitor contributes to its effectiveness in halting tumor progression by starving tumors of their blood supply.
Advantages of Axitinib
Targeted Cancer Therapy
Leverage the precision of Axitinib CAS 319460-85-0 for targeted cancer treatment, minimizing off-target effects and improving patient outcomes.
Anti-Angiogenic Power
Benefit from its role as an anti-angiogenic therapy for cancer, effectively blocking new blood vessel formation essential for tumor survival and growth.
Proven Efficacy in RCC
Utilize a compound recognized as a leading tyrosine kinase inhibitor for RCC, offering a proven treatment pathway for advanced renal cell carcinoma.
Key Applications
Renal Cell Carcinoma Treatment
Axitinib is a cornerstone in the treatment of advanced renal cell carcinoma, offering significant benefits to patients requiring effective therapies.
Oncology Research
Its role as a VEGF and PDGF inhibitor makes it an invaluable tool in preclinical and clinical research for various cancer types.
Pharmaceutical Synthesis
As a high-quality pharmaceutical intermediate for cancer drugs, it supports the development and manufacturing of life-saving medications.
Biochemical Research
Researchers utilize Axitinib for its specific kinase inhibition properties, aiding in the understanding of cellular signaling pathways in cancer development.